Compounds > pyrroles
Page last updated: 2024-08-18

pyrroles and levodopa

pyrroles has been researched along with levodopa in 13 studies

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (30.77)18.2507
2000's4 (30.77)29.6817
2010's4 (30.77)24.3611
2020's1 (7.69)2.80

Authors

AuthorsStudies
Capiris, T; Connor, DT; Heffner, TG; MacKenzie, RG; Miller, SR; Pugsley, TA; Unangst, PC; Wise, LD1
Althaus, JS; Fici, GJ; VonVoigtlander, PF1
Barber, A; Bender, HM; Gottschlich, R; Greiner, HE; Harting, J; Mauler, F; Seyfried, CA1
Boxer, PA; Gregory, TF; Meltzer, LT; Serpa, KA; Wise, LD; Wright, JL1
Hanger, D; Joyce, JN; Reploge, M; Yarkov, AV1
Brotchie, JM; Crossman, AR; Millan, MJ; Nicholson, SL; Ravenscroft, P; Silverdale, MA1
Babita, K; Tiwary, AK1
Brotchie, JM; Fox, SH; Johnston, T; Millan, MJ; Reyes, G; Visanji, NP1
Brocco, M; Mela, F; Millan, MJ; Morari, M1
Aman, A; Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB1
Caliskan, A; Caliskan, S; Kamaci, M; Yildiz, HB; Yilmaz, H1
Brotchie, JM; Espinosa, MC; Fox, SH; Huot, P; Johnston, TH; Koprich, JB; Reyes, MG1
Hasantabar, V; Lakouraj, MM; Rezaei, M1

Other Studies

13 other study(ies) available for pyrroles and levodopa

ArticleYear
Chromeno[3,4-c]pyridin-5-ones: selective human dopamine D4 receptor antagonists as potential antipsychotic agents.
    Journal of medicinal chemistry, 1997, Aug-15, Volume: 40, Issue:17

    Topics: Animals; Antipsychotic Agents; CHO Cells; Cloning, Molecular; Cricetinae; Dopamine D2 Receptor Antagonists; Humans; Kinetics; Levodopa; Models, Chemical; Piperazines; Pyridines; Pyridones; Pyrroles; Rats; Receptors, Dopamine D2; Receptors, Dopamine D4; Structure-Activity Relationship; Sulfonamides

1997
Pharmacological approaches to counter the toxicity of Dopa.
    Amino acids, 1998, Volume: 14, Issue:1-3

    Topics: Animals; Benzothiazoles; Cells, Cultured; Cerebellum; Cytoplasmic Granules; Glutathione; Levodopa; Neuroprotective Agents; Pramipexole; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Selegiline; Thiazoles; Vitamin E

1998
Effects of GR-89696 and the novel peripherally selective OP2 agonists, EMD-61569 and EMD-61747, against focal cerebral ischemia in the rat.
    Methods and findings in experimental and clinical pharmacology, 1999, Volume: 21, Issue:2

    Topics: Animals; Binding, Competitive; Brain Edema; Brain Ischemia; Cerebral Arteries; Levodopa; Ligation; Male; Neuroprotective Agents; Piperazines; Pyrroles; Pyrrolidines; Rabbits; Rats; Rats, Inbred F344; Rats, Wistar; Receptors, Opioid, kappa

1999
Discovery of subtype-selective NMDA receptor ligands: 4-benzyl-1-piperidinylalkynylpyrroles, pyrazoles and imidazoles as NR1A/2B antagonists.
    Bioorganic & medicinal chemistry letters, 1999, Oct-04, Volume: 9, Issue:19

    Topics: Animals; Disease Models, Animal; Imidazoles; Levodopa; Ligands; Molecular Structure; Oxidopamine; Parkinsonian Disorders; Piperidines; Pyrazoles; Pyrroles; Rats; Receptors, N-Methyl-D-Aspartate

1999
Behavioral effects of dopamine agonists and antagonists in MPTP-lesioned D3 receptor knockout mice.
    Pharmacology, biochemistry, and behavior, 2003, Volume: 76, Issue:3-4

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Autoradiography; Behavior, Animal; Benzopyrans; Carbidopa; Cocaine; Dopamine Agents; Dopamine Agonists; Dopamine Antagonists; Dopamine Plasma Membrane Transport Proteins; Female; Grooming; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Nerve Tissue Proteins; Oxazines; Pyrroles; Radiopharmaceuticals; Receptors, Dopamine D2; Receptors, Dopamine D3; Stereotyped Behavior

2003
Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.
    Experimental neurology, 2004, Volume: 188, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzopyrans; Brain; Callithrix; Disease Models, Animal; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Indoles; Levodopa; Parkinsonian Disorders; Pyrroles; Receptors, Dopamine D2; Receptors, Dopamine D3

2004
Skin lipid synthesis inhibition: a possible means for enhancing percutaneous delivery of levodopa.
    Current drug delivery, 2004, Volume: 1, Issue:4

    Topics: Administration, Cutaneous; Animals; Anticholesteremic Agents; Antiparkinson Agents; Atorvastatin; beta-Alanine; Calcium Channel Blockers; Calcium Chloride; Cholesterol; Dose-Response Relationship, Drug; Ethanol; Female; Heptanoic Acids; In Vitro Techniques; Levodopa; Male; Pyrroles; Rats; Rats, Wistar; Serine C-Palmitoyltransferase; Skin; Sphingosine; Time Factors; Verapamil

2004
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Neurobiology of disease, 2009, Volume: 35, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzopyrans; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger

2009
The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
    Neuropharmacology, 2010, Volume: 58, Issue:2

    Topics: Animals; Antiparkinson Agents; Benzopyrans; Disability Evaluation; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Hypokinesia; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; Time Factors; Treatment Outcome

2010
L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    The Journal of pharmacology and experimental therapeutics, 2012, Volume: 342, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain; Drug Interactions; Dyskinesias; Female; Levodopa; Macaca; Male; Motor Activity; Parkinson Disease; Pyridines; Pyrroles; Receptors, Dopamine D4

2012
L-Dopa synthesis catalyzed by tyrosinase immobilized in poly(ethyleneoxide) conducting polymers.
    International journal of biological macromolecules, 2013, Volume: 56

    Topics: Biocatalysis; Electric Conductivity; Electrodes; Enzyme Stability; Enzymes, Immobilized; Hydrogen-Ion Concentration; Kinetics; Levodopa; Monophenol Monooxygenase; Polyethylene Glycols; Polymers; Pyrroles; Temperature

2013
L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.
    Behavioural pharmacology, 2015, Volume: 26, Issue:1-2

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinsonian Disorders; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Species Specificity

2015
Synthesis, characterization and in-vitro prolonged release of L-DOPA using a novel amphiphilic hydrogel based on sodium alginate-polypyrrole.
    International journal of biological macromolecules, 2021, Dec-15, Volume: 193, Issue:Pt A

    Topics: Administration, Oral; Alginates; Antioxidants; Antiparkinson Agents; Drug Liberation; Fibroblasts; Humans; Hydrogels; Levodopa; Parkinson Disease; Polymers; Pyrroles

2021